Symptomatology, prognosis and clinical findings of STEMI as a ramification of COVID-19: A systematic review and proportion meta-analysis.
COVID-19
Cardiovascular disease
Mortality
ST-Segment myocardial infarction
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
27
12
2021
revised:
22
02
2022
accepted:
28
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
ppublish
Résumé
There is an increasing COVID-19 population with concurrent STEMI. SARS-CoV-2 poses a significant risk of hypercoagulable and/or prothrombotic events due to the disturbance in hemostasis by affecting all three components of the Virchow's triad. These abnormalities in hemostasis are an increased risk factor for cardiovascular events, including acute thrombotic occlusion of coronary arteries leading to myocardial infarction. The objective of this study is to collate the prognosis, symptomatology and clinical findings of COVID-19 adverse events causing STEMI. Databases were queried with various keyword combinations to find applicable articles. Cardiovascular risk factors, symptomatology, mortality and rates of PCI were analyzed using random-effect model. 15 studies with a total of 379 patients were included in the final analysis. Mean age of patients was 62.82 ± 36.01, with a male predominance (72%, n = 274). Hypertension, dyslipidemia and diabetes mellitus were the most common cardiovascular risk factors among these patients, with a pooled proportion of 72%, 59% and 40% respectively. Dyspnea (61%, n = 131) was the most frequent presenting symptom, followed by chest pain (60%, n = 101) and fever (56%, n = 104). 62% of the patients had obstructive CAD during coronary angiography. The primary reperfusion method used in the majority of cases was percutaneous coronary intervention (64%, n = 124). Mortality, which is the primary outcome in our study, was relatively high, with a rate of 34% across studies. Our findings show that most cases have been found in males, while the most common risk factors were Hypertension and Diabetes Mellitus. In most COVID-19 cases with ST-segment myocardial infarction, most hospitalized patients underwent primary percutaneous coronary intervention instead of fibrinolysis. The in-hospital mortality was significantly higher, making this report significant. As the sample size and reported study are considerably less, it warrants a further large-scale investigation to generalize it.
Sections du résumé
Background
UNASSIGNED
There is an increasing COVID-19 population with concurrent STEMI. SARS-CoV-2 poses a significant risk of hypercoagulable and/or prothrombotic events due to the disturbance in hemostasis by affecting all three components of the Virchow's triad. These abnormalities in hemostasis are an increased risk factor for cardiovascular events, including acute thrombotic occlusion of coronary arteries leading to myocardial infarction.
Objective
UNASSIGNED
The objective of this study is to collate the prognosis, symptomatology and clinical findings of COVID-19 adverse events causing STEMI.
Methods
UNASSIGNED
Databases were queried with various keyword combinations to find applicable articles. Cardiovascular risk factors, symptomatology, mortality and rates of PCI were analyzed using random-effect model.
Results
UNASSIGNED
15 studies with a total of 379 patients were included in the final analysis. Mean age of patients was 62.82 ± 36.01, with a male predominance (72%, n = 274). Hypertension, dyslipidemia and diabetes mellitus were the most common cardiovascular risk factors among these patients, with a pooled proportion of 72%, 59% and 40% respectively. Dyspnea (61%, n = 131) was the most frequent presenting symptom, followed by chest pain (60%, n = 101) and fever (56%, n = 104). 62% of the patients had obstructive CAD during coronary angiography. The primary reperfusion method used in the majority of cases was percutaneous coronary intervention (64%, n = 124). Mortality, which is the primary outcome in our study, was relatively high, with a rate of 34% across studies.
Conclusion
UNASSIGNED
Our findings show that most cases have been found in males, while the most common risk factors were Hypertension and Diabetes Mellitus. In most COVID-19 cases with ST-segment myocardial infarction, most hospitalized patients underwent primary percutaneous coronary intervention instead of fibrinolysis. The in-hospital mortality was significantly higher, making this report significant. As the sample size and reported study are considerably less, it warrants a further large-scale investigation to generalize it.
Identifiants
pubmed: 35284069
doi: 10.1016/j.amsu.2022.103429
pii: S2049-0801(22)00189-3
pmc: PMC8902059
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
103429Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
None.
Références
Catheter Cardiovasc Interv. 2021 Feb 15;97(3):E319-E326
pubmed: 32667726
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Circulation. 2020 Jun 23;141(25):2113-2116
pubmed: 32352306
J Am Coll Cardiol. 2020 Sep 15;76(11):1375-1384
pubmed: 32330544
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
Case Rep Cardiol. 2020 Aug 6;2020:8845627
pubmed: 32855827
Eur Heart J. 2022 Mar 14;43(11):1033-1058
pubmed: 34791157
Braz J Cardiovasc Surg. 2020 Aug 01;35(4):530-538
pubmed: 32864934
Am J Med Sci. 2021 Mar;361(3):403-405
pubmed: 33243433
Life Sci. 2020 Jul 15;253:117723
pubmed: 32360126
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211056800
pubmed: 34854348
Curr Cardiol Rep. 2020 Apr 14;22(5):31
pubmed: 32291526
J Cardiovasc Med (Hagerstown). 2021 May 1;22(5):417-419
pubmed: 32740444
Curr Opin Cardiol. 2021 Sep 1;36(5):589-596
pubmed: 34397465
Am J Cardiol. 2020 Sep 15;131:1-6
pubmed: 32732010
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
Curr Pharm Des. 2021;27(29):3198-3209
pubmed: 33045960
N Engl J Med. 2020 Jun 18;382(25):2478-2480
pubmed: 32302081
Med Clin (Engl Ed). 2021 Aug 13;157(3):114-117
pubmed: 34250244
Cardiovasc Res. 2020 Dec 1;116(14):2177-2184
pubmed: 32750108
Rev Cardiovasc Med. 2020 Sep 30;21(3):315-319
pubmed: 33070537
Rev Cardiovasc Med. 2020 Sep 30;21(3):399-409
pubmed: 33070544
Clin Case Rep. 2020 Jul 23;8(12):2436-2442
pubmed: 32837724
Ann Acad Med Singap. 2021 May;50(5):425-430
pubmed: 34100519
Hosp Pract (1995). 2021 Feb;49(1):12-21
pubmed: 32859138
Eur Heart J Case Rep. 2021 Feb 08;5(2):ytaa553
pubmed: 33644657
J Am Coll Cardiol. 2020 Sep 8;76(10):1168-1176
pubmed: 32679155
Pathobiology. 2021;88(1):15-27
pubmed: 33049751
Cardiovasc Res. 2020 Mar 1;116(4):829-840
pubmed: 31958135
Circ J. 2021 Sep 24;85(10):1701-1707
pubmed: 33658444
Atherosclerosis. 2020 Dec;314:58-62
pubmed: 33161318
Oxid Med Cell Longev. 2021 Aug 30;2021:4936571
pubmed: 34484561
Geroscience. 2020 Aug;42(4):1021-1049
pubmed: 32430627
Case Rep Cardiol. 2021 Aug 21;2021:9915650
pubmed: 34426772
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Circulation. 2019 Apr 30;139(18):e891-e908
pubmed: 30913893
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Catheter Cardiovasc Interv. 2021 Sep;98(3):E370-E378
pubmed: 33904638
Vascul Pharmacol. 2018 Jan;100:1-19
pubmed: 28579545
J Am Coll Cardiol. 2020 Nov 3;76(18):2043-2055
pubmed: 33121710
Int J Hematol. 2021 Jan;113(1):45-57
pubmed: 33161508
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Circulation. 2021 Feb 16;143(7):624-640
pubmed: 33191769
Exp Ther Med. 2022 Jan;23(1):10
pubmed: 34815762
Semin Cardiothorac Vasc Anesth. 2020 Dec;24(4):293-303
pubmed: 32706293